A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature ...

Pathological complete response at surgery was higher with INT230-6 pre-treatment plus Keynote-522 (5/7; 71.4%) than with Keynote-522 alone (2/6; 33%), with one evaluation pending. Grade ≥3 adverse ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free ...

This might be a long shot, but I was diagnosed with triple negative breast cancer, had a lumpectomy with clear margins and had a recurrence six months later. I am struggling with the treatment regimen ...

Triple-negative breast cancer lacks key receptors, requiring chemotherapy, immunotherapy, surgery, and radiation, with treatment tailored to cancer stage. Early-stage TNBC treatment often involves ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

CLEVELAND, Ohio — A shift toward personalized treatment for breast cancer, ways to help patients live longer without their cancer worsening and a shorter but equally effective treatment for a ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

These findings provide insights into triple-negative breast cancer etiology, disparities, and therapeutic response in African American women, a group that is underrepresented in genomic studies.

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease ...